| Metric | Value | Detail |
|---|---|---|
| Revenue | $48.2B | -0.2% YoY |
| Net income | $7.1B | 14.6% margin |
| Gross margin | n/a | Gross profit / revenue |
| Operating margin | n/a | Operating income / revenue |
| Return on equity | 38% | Net income / equity |
| Return on assets | 8% | Net income / assets |
| Revenue growth (YoY) | -0.2% | FY2024 to FY2025 |
| Revenue 3-yr CAGR | +1.4% | Compound annual |
| Diluted EPS | $3.47 | FY2025 |
| Debt-to-equity | 2.42 | Long-term debt / equity |
| Current ratio | 1.26 | Current assets / liabilities |
| Cash & equivalents | $10.2B | Balance sheet |
| Total assets | $90.0B | FY2025 year-end |
| Shareholders’ equity | $18.5B | FY2025 year-end |
| Share price | $57.58 | Delayed · 2026-07-10 |
| Market cap | $117.6B | Price × shares outstanding |
| P/E ratio | 16.7 | Market cap / net income |
| P/S ratio | 2.4 | Market cap / revenue |
| Dividend yield | 4.32% | Dividend / price |
Stock fundamentals · FY2025 · SEC 10-K data
Bristol-Myers Squibb Company (BMY) stock fundamentals
Bristol-Myers Squibb Company (BMY) reported $48.2B in revenue and $7.1B in net income in fiscal 2025, a 14.6% net margin, per its latest SEC 10-K filing. It carries a market capitalization of about $117.6B at a delayed share price. It scores 44/100 on WealthyBud's Investor Score, ranking #61 of 100 covered companies. Score is research, not investment advice.
Revenue (FY2025)
$48.2B
▼ -0.2% YoY
Net income
$7.1B
14.6% net margin
Market cap
$117.6B
Price $57.58 · delayed
P/E ratio
16.7
Price / earnings
Return on equity
38%
Net income / equity
Investor Score
44/100
#61 of 100 covered
Bristol-Myers Squibb Company fundamentals at a glance
The table summarizes Bristol-Myers Squibb Company's key financial figures for fiscal 2025 — revenue, profitability, returns, growth and balance-sheet strength — each taken from the company's SEC 10-K filing.
How profitable is Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company runs a 14.6% net margin and n/a gross margin in fiscal 2025, turning $48.2B of revenue into $7.1B of profit. Return on equity is 38% and return on assets 8%.
Is Bristol-Myers Squibb Company growing?
Bristol-Myers Squibb Company's revenue changed -0.2% in fiscal 2025 and compounded at +1.4% a year over three years, reaching $48.2B. Diluted earnings per share were $3.47 for the year.
| Fiscal year | Revenue | Growth |
|---|---|---|
| 2021 | $46.4B | n/a |
| 2022 | $46.2B | -0.5% |
| 2023 | $45.0B | -2.5% |
| 2024 | $48.3B | +7.3% |
| 2025 | $48.2B | -0.2% |
How is Bristol-Myers Squibb Company valued?
Bristol-Myers Squibb Company carries a market capitalization of $117.6B at a delayed share price of $57.58, trading at a 16.7 price-to-earnings ratio and 2.4 price-to-sales with a 4.32% dividend yield. Its Value subscore is 81/100 across the covered universe.
How financially healthy is Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company ended fiscal 2025 with $10.2B in cash, a debt-to-equity ratio of 2.42 and a current ratio of 1.26. Lower leverage and a current ratio above 1.0 signal a stronger balance sheet.
What is Bristol-Myers Squibb Company's Investor Score?
Bristol-Myers Squibb Company scores 44/100 on WealthyBud's Investor Score, #61 of 100 covered companies as of 2026-07-10. The score blends growth, profitability, returns on capital, balance-sheet strength and value into one percentile. It is a research opinion, not investment advice.
Investor Score
44/100
#61 of 100 covered companies
Subscores are percentile ranks (0–100) across the 100 covered companies, computed from the SEC fundamentals and delayed market price cited on this page. Data-derived opinion, not investment advice.
Bristol-Myers Squibb Company (BMY) stock FAQ
How much revenue does Bristol-Myers Squibb Company make?
Bristol-Myers Squibb Company (BMY) reported $48.2B in revenue in fiscal 2025, -0.2% versus the prior year, according to its SEC 10-K filing. Over the past three years its revenue has compounded at +1.4% a year.
Is Bristol-Myers Squibb Company profitable?
Yes. Bristol-Myers Squibb Company earned $7.1B in net income in fiscal 2025, a 14.6% net margin. Its return on equity was 38% and return on assets 8%, based on figures from its latest 10-K.
How fast is Bristol-Myers Squibb Company growing?
Bristol-Myers Squibb Company's revenue changed -0.2% year over year in fiscal 2025 and compounded at +1.4% annually over three years. Growth is one of four inputs to its WealthyBud Investor Score, scored 14/100 versus the covered universe.
What is Bristol-Myers Squibb Company's market cap and P/E ratio?
Bristol-Myers Squibb Company has a market capitalization of $117.6B at a delayed share price of $57.58, trading at a price-to-earnings ratio of 16.7 and price-to-sales of 2.4. Its dividend yield is 4.32%. Prices are delayed and illustrative.
What is Bristol-Myers Squibb Company's WealthyBud Investor Score?
Bristol-Myers Squibb Company scores 44/100, ranking #61 of 100 covered companies as of 2026-07-10. The score is a percentile blend of growth (14), profitability (41), returns on capital (64), balance-sheet strength (33) and value (81). It is a research opinion, not investment advice.
Where does this Bristol-Myers Squibb Company financial data come from?
Fundamentals come from Bristol-Myers Squibb Company's annual report (Form 10-K) filed with the SEC, via the public-domain EDGAR database. The share price used for market cap, P/E and yield is a delayed end-of-day quote, shown as illustrative; a production site would use a licensed real-time market-data feed.
Fundamentals are drawn from Bristol-Myers Squibb Company’s FY2025 Form 10-K filed with the
SEC (EDGAR, public domain), retrieved 2026-07-10. Share price is a delayed end-of-day quote; market cap, P/E, P/S
and dividend yield are illustrative and not real-time. The Investor Score is a data-derived research opinion.
Not investment advice.